Publication | Closed Access

Cost-Effectiveness of Pravastatin in Secondary Prevention of Coronary Artery Disease**This study was supported by Bristol-Myers Squibb, Plainsboro, New Jersey.

Preventive MedicineCardiovascular EpidemiologyCardiovascular DiseaseHealth EconomicsClinical EffectivenessSecondary PreventionOutcomes ResearchPharmacoeconomicsPharmacotherapyPreventive CardiologyCost EffectivenessPublic HealthMedicineNew JerseyEpidemiologyCoronary Artery DiseaseBristol-myers Squibb